Literature DB >> 3021515

Antibody response against early antigens in Herpesviridae infections.

M P Landini.   

Abstract

For the serological diagnosis of Herpesvirus infection, increasing use is made of the determination of the antibodies against virus-specific early antigens. The presence of serum antibody to early antigens is a widely accepted marker of acute Epstein-Barr virus infection or Varicella-Zoster virus infection. Controversial data are present in the literature about the significance of Cytomegalovirus early antigens antibody response. This is discussed in view of the possibility that controversial results could be due to different methods used to produce early antigens by different authors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3021515     DOI: 10.1007/bf00162314

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  16 in total

1.  The synthesis of herpes simplex virus proteins in the absence of virus DNA synthesis.

Authors:  K L Powell; D J Purifoy; R J Courtney
Journal:  Biochem Biophys Res Commun       Date:  1975-09-02       Impact factor: 3.575

2.  Antibodies against cytomegalovirus-induced early antigens (CMV-EA) in immunosuppressed renal-allograft recipients.

Authors:  T H The; H K Andersen; E S Spencer; G Klein
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

3.  Antibody reactivity to human and vervet cytomegalovirus early antigen(s) in sera from patients with active cytomegalovirus infections and from asymptomatic donors.

Authors:  J L Waner; S A Biano
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

4.  Immunoglobulin G to virus-specific early antigens in congenital, primary, and reactivated human cytomegalovirus infections.

Authors:  G Gerna; P M Cereda; E Cattaneo; G Achilli; M G Revello
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

5.  Infectious mononucleosis and its relationship to EB virus antibody. A joint investigation by university health physicians and P.H.L.S. laboratories.

Authors: 
Journal:  Br Med J       Date:  1971-12-11

6.  Virus replication and localization of varicella-zoster virus antigens in human embryonic fibroblast cells infected with cell-free virus.

Authors:  K Yamanishi; Y Matsunaga; T Ogino; M Takahashi; A Takamizawa
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

7.  Determination of antibodies against cytomegalovirus-induced early antigens by using rabbit lung fibroblasts. Brief report.

Authors:  I Färber; P Wutzler; M Sprössig; H Schweizer
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

8.  Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine.

Authors:  A D Friedman; S Michelson; S A Plotkin
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

9.  Seroconversion to virus-specific pre-early nuclear antigens in infants with primary cytomegalovirus infection.

Authors:  S Chiba; T Motokawa; T Tamura; H Hanazono; M Kamada; Y Chiba; T Nakao
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

10.  Detection of antibody to cytomegalovirus early antigen in vaccinated, normal volunteers and renal transplant candidates.

Authors:  A D Friedman; T Furukawa; S A Plotkin
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

View more
  2 in total

1.  Comparison of immunoblotting with other serological methods and virus isolation for the early detection of primary cytomegalovirus infection in allograft recipients.

Authors:  H Miller; B McCulloch; M P Landini; E Rossier
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

2.  Lack of correlation between virus detection and serologic tests for diagnosis of active cytomegalovirus infection in patients with AIDS.

Authors:  T Lazzarotto; P Dal Monte; M C Boccuni; A Ripalti; M P Landini
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.